Charles River Labs appoints Dr. Craig B. Thompson to Board

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Board expanded from 10 to 11; Dr. Thompson appointed effective Dec. 5, 2022.
Appointed to Science & Technology Committee and Strategic Planning & Capital Allocation Committee.
Initial pro-rata equity award valued at $255,500 (50% RSUs, 50% stock options).
Thompson is former CEO of Memorial Sloan Kettering (2010-2022) and current Regeneron board member.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Craig B. Thompson

Director

CRL · CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Effective: 2022-12-05
Filed: December 6, 2022, 6:59 PM ET

Following the size increase of the Board, the Board filled the vacancy and appointed Dr. Craig B. Thompson to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Craig B. Thompson was appointed as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..

Action: appointed
Role: Director

Exact text from the filing

Following the size increase of the Board, the Board filled the vacancy and appointed Dr. Craig B. Thompson to the Board.

View on SEC.gov

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. filing history →

Source: SEC EDGAR

accession 0001100682-22-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.